Replies to post #198955 on Biotech Values

[DewDiligence]

Barron’s SNY piece does not even mention REGN, which is a pretty significant omission:

http://www.barrons.com/articles/sanofi-is-on-the-mend-1453527231

[DewDiligence]

Warp Drive inks antibiotic-discovery deal with Roche:

http://www.businesswire.com/news/home/20171015005071/en/Warp-Drive-Bio-Forms-Strategic-Collaboration-Advance

Under the terms of the agreement, Roche has an option for an exclusive worldwide license to develop and commercialize certain antibiotic classes that emerge from the collaboration, triggered upon the selection of a drug development candidate from the particular class. Warp Drive will retain worldwide rights to all other novel antibiotic classes from the collaboration.

Warp Drive will receive up to $87 million in upfront payment, option fees, and milestone payments for preclinical events, and up to $300 million in payments related to specific clinical, regulatory and sales milestones on products licensed to Roche. In addition, for products licensed to Roche, Warp Drive is eligible to receive tiered royalties for development candidates up to double digits on future net sales.